HDACi induces apoptosis of osteosarcoma cells by inhibiting the MAPK pathway
HDACi induces apoptosis of osteosarcoma cells by inhibiting the MAPK pathway
Investigate the malignant biological effects of the histone deacetylase inhibitor (HDACi) in osteosarcoma (OS) and study the underlying mechanisms through mRNA sequencing. ... HDACi can significantly inhibit the malignant biological abilities of OS cells and induce apoptosis in OS cells by suppressing the MAPK/ERK pathway.
Osteosarcoma is highly aggressive with poor prognosis; targeting epigenetic regulators such as HDACs may provide a novel therapeutic avenue.
Evidence level: Számítógépes vagy elméleti. Modellből vagy adatbányászatból származó jel.
Related signals
- Telisotuzumab Vedotin + Osimertinib for Non‑Small Cell Lung Cancer
- Ramucirumab plus erlotinib in patients with untreated, EGFR‑mutated, advanced non‑small‑cell lung cancer (RELAY): a randomised, double‑blind, placebo‑controlled, phase 3 trial
- Recent advancements in lung cancer research: a narrative review
- Advances in Non-Small Cell Lung Cancer: Current Insights and Future Directions
- Structured proxy features for multimodal NSCLC survival prediction from pretreatment CT